Insiders who bought Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) stock lover the last 12 months are probably not as affected by last week’s 20% loss. Even after accounting for the recent loss, the US$1.26m worth of stock purchased by them is now worth US$1.84m or in other words, their investment continues to give good returns.

While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

The Last 12 Months Of Insider Transactions At Rani Therapeutics Holdings

In the last twelve months, the biggest single purchase by an insider was when Executive Chairman Mir Imran bought US$1.3m worth of shares at a price of US$0.60 per share. We do like to see buying, but this purchase was made at well below the current price of US$0.88. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.

Does Rani Therapeutics Holdings Boast High Insider Ownership?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. Based on our data, Rani Therapeutics Holdings insiders have about 3.0% of the stock, worth approximately US$2.9m. I generally like to see higher levels of ownership.

So What Do The Rani Therapeutics Holdings Insider Transactions Indicate?

It doesn't really mean much that no insider has traded Rani Therapeutics Holdings shares in the last quarter. But insiders have shown more of an appetite for the stock, over the last year. We'd like to see bigger individual holdings. However, we don't see anything to make us think Rani Therapeutics Holdings insiders are doubting the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Rani Therapeutics Holdings.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.